Haemostasis is a defence mechanism that has evolved to protect organisms from losing their circulating fluid. We have previously introduced zebrafish as a model to study the genetics of haemostasis to identify novel genes that play a role in haemostasis. Here, we identify a zebrafish mutant that showed prolonged time to occlusion (TTO) in the laser injury venous thrombosis assay. By linkage analysis and fine mapping, we found a mutation in the orphan G protein-coupled receptor 34 like gene (gpr34l) causing a change of Val to Glu in the third external loop of Gpr34l. We have shown that injection of zebrafish gpr34l RNA rescues the prolonged TTO defect. The thrombocytes from the mutant showed elevated levels of cAMP that supports the defective thrombocyte function. We also have demonstrated that knockdown of this gene by intravenous Vivo-Morpholino injections yielded a phenotype similar to the gpr34l mutation. These results suggest that the lack of functional Gpr34l leads to increased cAMP levels that result in defective thrombocyte aggregation.
Summary
Haemostasis is a defence mechanism that has evolved to protect organisms from losing their circulating fluid. We have previously introduced zebrafish as a model to study the genetics of haemostasis to identify novel genes that play a role in haemostasis. Here, we identify a zebrafish mutant that showed prolonged time to occlusion (TTO) in the laser injury venous thrombosis assay. By linkage analysis and fine mapping, we found a mutation in the orphan G protein-coupled receptor 34 like gene (gpr34l) causing a change of Val to Glu in the third external loop of Gpr34l. We have shown that injection of zebrafish gpr34l RNA rescues the prolonged TTO defect. The thrombocytes from the mutant showed elevated levels of cAMP that supports the defective thrombocyte function. We also have demonstrated that knockdown of this gene by intravenous Vivo-Morpholino injections yielded a phenotype similar to the gpr34l mutation. These results suggest that the lack of functional Gpr34l leads to increased cAMP levels that result in defective thrombocyte aggregation.
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In mammals, the haemostatic response involves platelet activation and aggregation followed by activation of the coagulation cascade, together leading to a thrombus formation (Davidson et al, 2003; Jagadeeswaran et al, 2005) . Platelets act through several membrane receptors including G protein-coupled receptors, which signal to recruit additional platelets into the growing thrombus (Offermanns, 2006) . Despite considerable progress in platelet function and characterization of a few factors, given the fact that there are a large number of genes with no known function in vertebrate genomes, it is possible that a fraction of these novel genes with the unknown function may contribute to platelet function. Thus, more new factors controlling platelet function may remain to be identified.
In our previous work, we introduced zebrafish as a genetic model to study mammalian haemostasis (Jagadeeswaran et al, 2005; Khandekar et al, 2012) . We also established a global laser-induced thrombosis method to assay all the factors of the haemostatic system (Jagadeeswaran et al, 2011) .
Forward genetic methods using N-ethyl-N-nitrosourea (ENU) mutagenesis and functional screens using the global assay and other haemostatic assays have been successfully employed in our laboratory, resulting in establishing the proof of principle that the zebrafish model could be used to identify novel mutations in haemostatic pathways (Jagadeeswaran et al, 2000; Gregory et al, 2002) . Recent studies using genome-wide analysis have identified novel genes associated with platelet function, whose functional roles were confirmed by using our zebrafish haemostasis model and laser injury methods, as well as by using zebrafish in which thrombocytes are labelled with green fluorescence protein (GFP) (O'Connor et al, 2009; Gieger et al, 2011) . In our continuing screening efforts, we identified a zebrafish mutant that has prolonged time to occlusion in the laser-induced venous thrombosis assay, identified the gene as an orphan G protein-coupled receptor (GPCR) gene, gpr34l, and established the role of Gpr34l in thrombocyte function.
Methods

Fish breeding and mutagenesis
The maintenance and breeding of zebrafish were performed as described previously (Gregory et al, 2002) . All procedures were approved by the Institutional Animal Care and Use Committee of the University of North Texas and animal experiments were performed in compliance with the institutional guidelines. ENU mutagenesis was carried ou according to the published protocols (Solnica-Krezel et al, 1994) .
Screening and mutant selection
A four-generation natural crosses mutant screen using AB and TU strains was conducted with the time to occlusion of the vessel (TTO) assay after laser injury of a vein of 4 days post-fertilisation (dpf) larvae immobilized in agarose, as described earlier (Gregory et al, 2002; Dosch et al, 2004) . Briefly from the F3 heterozygous progeny of an individual family, six random mating pairs were set up for brother-sister/cousin mating, and in the resulting F4,10-20 larvae from each pair were screened by TTO assay. If 25% of the 10-20 larvae screened showed a TTO response >60 s, then the parents were considered presumptive heterozygotes for a mutation affecting haemostasis. The presumptive heterozygotes were then subsequently bred to obtain sufficient numbers of mutants for mapping. Mutant larvae with the prolonged TTO phenotype and larvae that had normal TTO were recovered from agarose by releasing them into the water after the thrombus dissolved. The larvae recovered from the agarose were grown to adulthood.
Linkage mapping and sequencing
DNA from each of the larva recovered from agarose was isolated by mixing 10 ll of DNA extraction buffer (10 mmol/l Tris pH 8Á0, 2 mmol/l EDTA, 0Á2% Triton X-100, and 200 lg/ ml Proteinase K) with a larva and incubated at 55°C overnight. The mixture was boiled for 10 min and centrifuged for 1 min at 10 0009 g. The supernatant was used for polymerase chain reaction (PCR). The 20 DNAs from each of the mutant larvae were mixed and pooled together, and a similar pool of DNA was made from control larvae to map the gene by bulked segregant analysis. These DNAs were amplified with 230 microsatellite markers, provided by MapPairs (Invitrogen Inc., Carlsbad, CA), that span the zebrafish genome at approximately 10 centimorgan (cM) intervals. The resulting amplified products were run on agarose gels. The suspected genes were amplified by PCR and sequenced by dideoxy sequencing method using the ABI capillary sequencer (Lone Star Laboratories, Houston, TX).
Thrombocyte aggregation assay
Blood was collected by making an incision in a caudal axial vein or dorsal aorta and mixed with the 0Á25 volume of 3Á8% sodium citrate in phosphate-buffered saline (PBS) (Jagadeeswaran et al, 1999) . Thrombocyte aggregation was assessed by whole blood aggregation using a plate tilt assay as previously described (Jagadeeswaran et al, 1999) . One ll of citrate-buffered blood was added to a microtitre plate well containing 8 ll PBS and 1 ll of agonist. The agonists used were 0Á2 mmol/l ADP reagent, 1 mg/ml collagen, 1 mmol/l epinephrine, 120 mmol/l arachidonic acid and 5 lg/ml zebrafish PAR1 peptide, SFSGFF. All the above agonists were purchased from Sigma-Aldrich (St. Louis, MO) except for SFSGFF which was custom ordered from Biosynthesis, Lewisville, TX. The microtitre plate was tilted manually every minute for 40 min at 25°C to determine the time taken to stop the flow of blood down the walls of the well, i.e., time taken for aggregation of thrombocytes (TTA).
Vivo-morpholino injections
An antisense gpr34l Vivo-Morpholino (Vivo-MO), 5'-AAATCAGGTTGGGTTGAGACAACAT-3' against the translational start of zebrafish gpr34l mRNA was purchased from Gene-Tools LLC (Philomath, OR) for synthesis. A control Vivo-MO 5 0 -CCTCTTACCTCAGTTACAATTTATA-3 0 was also purchased from Gene-Tools. Approximately 5 ll Vivo-MOs 0Á5 mmol/l was taken in the 27G1 1/4 needle, such that the only Vivo-MO solution remained in the needle. For injection, zebrafish were anesthetized, and the needle was placed into the region that is located between the second and third body stripes closer to the anal pore and at right angles to the location of the inferior vena cava. It was then gently pushed to insert into the vessel; the syringe piston was immediately pushed gently to inject the contents. Blood was collected after 48 h and used in thrombocyte functional analysis.
Cyclic AMP assay
The intracellular cAMP content was measured using a commercially available cAMP Enzyme Immunoassay kit (SigmaAldrich) according to the assay protocol provided by the manufacturer. Briefly, 4 ll of blood from zebrafish was collected with 1 ll of 3Á8% sodium citrate in PBS. After centrifugation at 5009 g for 2 min at 4°C, the upper 2 ll layer, enriched with thrombocytes, was used in the assay. The colour developed in the reaction was read at 405 nm by using a ThermoMax Microplate Reader (Molecular Devices Co., Menlo Park, CA).
Reverse transcription PCR (RT-PCR) analysis
Zebrafish blood was collected as described above. Thrombocytes were prepared by the immunoselection method described previously (Kulkarni et al, 2012) . Total RNA from the zebrafish thrombocytes was prepared with the Absolute RNA kit (Agilent Technologies, Wilmington, DE). The forward primer 5'-ACCCTGCTAGTGCTGTGT-3' and reverse primer 5'-GATGTAGAAACTAATAAA-3' for zebrafish gpr34l were custom synthesized (Biosynthesis). RT-PCR was performed as described earlier (Kim et al 2010) . DNaseI, RNase-free was purchased from Thermo Scientific. One lg of RNA was incubated with one unit of DNaseI according to manufacturer's protocol, and the DNaseI-treated RNA was used in RT-PCR,
Mutant rescue
Full-length zebrafish gpr34l cDNA, amplified using the Superscript One-Step RT-PCR kit (Invitrogen) and the RNA (prepared as described above), forward primer 5'-AAAA-GATCTATGTTGTCTCAACCCAACCTG-3' and reverse primer 5'-AAAAGATCTTCAAATCTCCGTCAGCGAGCG-3', that have BglII restriction sites, was cloned into pSP64T plasmid (courtesy of Dr. Melton's laboratory, Harvard University). The mutant gpr34l cDNA was generated by using RT-PCR on mutant RNA. Each sense RNA was synthesized from linearized pSP64T plasmids containing the entire coding region of the above cDNAs using the SP6/T7 Transcription kit (Roche Applied Sciences, Indianapolis, IN) according to the manufacturer's protocol. An aliquot (100 pg) of the above individual RNAs were injected into single cell embryos derived from homozygous mutant fish. 4 dpf larvae were used for laser-induced venous thrombosis as described above. All of the above primers were synthesized by Biosynthesis.
Immunohistochemistry
Polyclonal antibodies against zebrafish Gpr34l peptide SNPFFNFSIRHPVTTRFEE were custom ordered from Alpha Diagnostic Intl. Inc., San Antonio, TX. Pre-immune sera were also supplied by the same vendor. Immunofluorescence was performed on freshly prepared blood smears from zebrafish. The slides were fixed with 70% cold ethanol for 15 min and rinsed with PBS three times. Zebrafish blood smears were incubated with 20 ll of 1 mg/ml of rabbit polyclonal antisera against the zebrafish Gpr34l peptide under a coverslip for 1 h at 4°C. After removal of the coverslip, the slides were rinsed with PBS three times, then incubated with fluorescein isothiocyanate-conjugated rabbit anti-sheep IgG (Sigma-Aldrich) for 1 h at 4°C. The slides were rinsed again with PBS followed by a brief rinse with water, and then photographed for immunofluorescence using a Nikon Eclipse 80i microscope (Nikon, Melville, NY, USA). The intensities of the thrombocyte immunofluorescence were quantified by NIS-Elements AR 2.30 software from Nikon. Pre-immune serum was used in place of polyclonal antisera as controls.
Statistical analysis
Statistical analysis was performed using Sigma Plot 10 with Sigma Stat integration software (Systat Software, Inc., San Jose, CA, USA). Statistical significance was assessed by ANOVA and a P < 0Á05 was considered significant.
Results
In our previous work, we introduced the zebrafish model using both forward and reverse genetic methods to study mammalian haemostasis, a process that protects the vertebrate organism from loss of blood from their vessels in the event of injury (Jagadeeswaran et al, 2005) . We have hitherto identified a zebrafish mutant by screening zebrafish larvae with a laser-induced thrombosis assay that measures haemostasis (Gregory et al, 2002) . We have continued this screening with the TTO thrombosis assay using ENU mutagenized zebrafish generated with natural crosses. During this screen, we found a mutant p37ATUZ that showed TTO > 60 s.
To map this mutant, we set up crosses between the pairs of p37ATUZ heterozygotes that showed the mutant phenotype in the progeny, performed laser thrombosis assays on approximately 1500 larvae of the above crosses, isolated 384 larvae that demonstrated a prolonged TTO, and prepared their genomic DNAs. We also isolated DNA from larvae that did not demonstrate any phenotype for use as controls. We then used a pool of 20 DNAs from each control and mutant larvae and performed PCRs on these pools using 230 microsatellite polymorphic markers, which were distributed approximately 10 cM apart and covered the entire zebrafish genome to identify markers that cosegregated with the prolonged TTO phenotype. In this pooled bulk segregant method the polymorphic bands were clearly separated, and it was easy to detect a marker linked to the mutant phenotype from among the 230 markers tested (Michelmore et al, 1991) . We found a pattern of bands that departed from the control amplifications with one marker, z3275 and this unique pattern was considered as evidence of linkage of the mutant TTO phenotype to this marker. Once the z3275 marker was found, individual DNAs of the 20 mutant larvae were amplified to confirm the cosegregation. This marker was located on linkage group 4 (shown by the arrow in Fig 1) . To detect the closest marker that cosegregates with the mutant phenotype, we examined the zebrafish genome, found other flanking markers, and repeated the experiment individually on the 384 larvae with prolonged TTO. The number of recombinants out of the 384 mutants is given in Fig 1. One of the marker (fc85f03.x1) showed a recombinant frequency of zero; this was determined to be the closest marker to the mutant gene. Examination of the genome near this marker (Fig 1) suggested that an orphan GPCR gene, gpr34l, and the mpp1 gene were candidate genes (since this linkage was identified, the location of this marker has been changed to a different linkage group in zv9 version of ENSEMBL database (https://mar2015.archive.ensembl.org/Danio_rerio/ Info/Index); nevertheless, the gene and the marker locations have not changed). We sequenced both these candidate genes from the mutants and found no mutations in mpp1 compared to normal AB and TU controls. However, sequence analysis of mutant gpr34l revealed a T to A transversion in the third external loop of GPCR compared to normal AB and TU controls. This transversion resulted in a change from Val to Glu at position 300 in Gpr34l (V300D) (Fig 2) . We also found the presence of the mutant phenotype across two generations, demonstrating that the mutant phenotype is heritable. We selected from breeding heterozygous gpr34l mutants the homozygous larvae that had prolonged TTO, recovered them from agarose and grew them to adults.
We tested whether gpr34l is expressed in thrombocytes of adult zebrafish by RT-PCR and found a positive gpr34l amplification using thrombocyte RNA (Fig 3) . We also confirmed that thrombocytes have Gpr34l by immunohistochemical methods (Fig 4) . We then cloned full-length gpr34l cDNA from wild-type (normal) zebrafish into an expression vector and prepared RNA by in vitro transcription. This gpr34l RNA was injected into mutant embryos obtained from breeding homozygous mutant adults at the single-to the four-cell stage. We performed laser thrombosis experiments on the larvae hatched from these RNA-injected embryos. We found that the TTO of the injected mutant larvae was significantly shorter than that of the control gpr34l mutant RNA injected larvae (Fig 5) . These results provided evidence that the mutant phenotype was rescued and confirmed that the gpr34l gene does affect haemostatic function.
We then tested whether the mutant fish thrombocytes aggregate in response to agonists using whole blood aggregation by plate tilt assay (Jagadeeswaran et al, 1999) . We used higher concentrations of agonist compared to those used in human platelet aggregation assays because the blood sample is not stirred in our assay and the introduced blood passes through the buffer containing agonist in a few seconds and settles at the bottom of the well. Using the above assay, the blood of the homozygous adult zebrafish showed no thrombocyte aggregation until 40 min in the presence of the known agonists tested, such as ADP, collagen, epinephrine and arachidonic acid, whereas the control thrombocytes aggregated more rapidly ( Table I ). Given that one of the general pathways important in inhibiting platelet activation, is an increase in cyclic AMP (cAMP), and not even one agonist activated mutant thrombocytes, the thrombocyte activation was most probably being inhibited by increase in cAMP levels. Therefore, we tested the thrombocyte-enriched white cell fraction for cAMP levels and, as predicted, cAMP levels were high in these mutant fish (Fig 6) . These results suggested that the gpr34l mutation is responsible for elevated cAMP regulation.
We then tested how the knockdown of Gpr34l would affect cAMP levels in wild-type adult thrombocytes. For this, we used the Vivo-MO technology developed in our laboratory. The proof of principle was established using intravenous injections of Vivo-MO against glycoprotein IIb into adult zebrafish that resulted in the knockdown of specific proteins in thrombocytes (Kim et al, 2010) . We then performed knockdowns of gpr34l using Vivo-MOs targeting ribosome binding sites so that the translation of gpr34l is blocked. We found the thrombocyte-enriched cells yielded increased levels of cAMP similar to the mutant results as shown in Fig 6. We also found a reduction of Gpr34l antibody staining on the thrombocytes (Fig 7) .
Discussion
In this work, using ENU mutagenesis of zebrafish, we identified a mutation in an orphan GPCR by linkage analysis and positional cloning. Although our earlier work on haemostasis screens provided proof of principle of screening and identification of marker that suggested linkage to the known prothrombin gene, we did not find any novel mutation. The mutant reported here is novel and has not been shown to be associated with any other phenotypes. Thus, it should be possible to use the above approach to detect novel mutations in haemostasis in the future.
Our results showed that a mutation in gpr34l and the knockdown of Gpr34l both resulted in the loss of function of Gpr34l and led to the increased cAMP production. It is well known that the levels of intracellular cAMP are regulated via the Gnas (also termed Gs) and Gnai (also termed Gi alpha) subunits of heterotrimeric G proteins, which couple to adenylate cyclase to respectively stimulate or inhibit cAMP production. Because ligand binding is required for G protein activation, it is difficult to conceive the ligand binding to activate Gnas or suppress Gnai in the knockdown scenario. Thus, the mechanism of activation of adenyl cyclase by the loss of Gpr34l, as noted in the knockdown results, appears to be unique and puzzling.
In the absence of Gpr34l, the increased cAMP levels due to the activation of Gnas or suppression of Gnai could be explained by the following models. As GPCRs are known to form heterodimers, in the model involving Gnas, we propose that, in normal circumstances, Gpr34l is inhibitory to a Gnas-coupled GPCR. The agonist for this Gnas-coupled GPCR mitigates the Gpr34l-mediated inhibition of Gnascoupled receptor. This loss of inhibition leads to the activation of Gnas, resulting in elevated cAMP levels. In this model, when the Gpr34l is mutated or lost, it also reduces Gpr34l-mediated inhibition of Gnas pathway and activates adenylate cyclase. Similarly, in the model involving Gnai, in normal circumstances, Gpr34l is a positive regulator of Gnaicoupled GPCR. In the presence of the ligand to Gnaicoupled GPCR, these two receptors together dictate the inhibition of the cAMP formation. When the Gpr34l is mutated or lost, the Gnai-mediated inhibition of adenylate cyclase is lost and, thus, leads to increased cAMP. Future work is needed to resolve which model is valid. Given that our models predict that the Gpr34l is either an inhibitor or an activator of another GPCR, Gpr34l per se may not have a ligand. Alternatively, if both Gnai-coupled GPCR and Gnas-coupled GPCR have the same ligand, the mutation or loss of Gnaicoupled GPCR may also result in increased cAMP levels due to the lack of inhibition of cAMP generation. In humans, an increase in GNAS function or a defect in GNAI signalling has been shown to be a risk factor for bleeding due to increased levels of cAMP (Noe et al, 2010) . However, there are a limited number of reported cases where cAMP levels are elevated in platelets. A patient of a partial trisomy 18p had increased levels of cAMP due to the GNAS activation. This increased GNAS activation has been attributed to the action of pituitary adenylate cyclase activating peptide on vasoactive intestine peptide/pituitary adenylate cyclase activating peptide receptor 1, which is coupled to adenylate cyclase activation (Freson et al, 2004) . In another case, the platelets of two unrelated families showed increased sensitivity to inhibition by agents, such as prostacyclin, that increase cAMP levels and thus showing inducible hyperfunction of GNAS. In these patients, paternally imprinted GNAS (Gs) gene dictates the production of alternatively spliced mRNAs, resulting in isoforms that included an extra-large GNAS due to an indel (Freson et al, 2001) . Since the extralarge GNAS is not known to be linked to any receptor, the mechanisms of cAMP increase in these patients are not known. Similarly, upon activation, GNAI-deficient patient platelets failed to inhibit forskolin-stimulated cAMP (Patel et al, 2003) . Interestingly, a mutation in the ADP receptor, P2Y12, which produces a marked reduction in binding of ADP to this receptor, failed to lower the cAMP of platelets that were pre-incubated with prostaglandin E1 (Cattaneo et al, 1992; Nurden et al, 1995) .
Given that the cAMP assay is not used in the laboratory diagnosis of platelet disorders and is used only in research laboratories, more patients with increased cAMP have not been reported. However, in a recent study of high throughput sequencing, the molecular mechanism was not certain in 76 of 300 patients (Simeoni et al, 2016) . Interestingly 70 of these 76 patients did not have any observable pathological variants (Simeoni et al, 2016) . These results suggested that the uncharacterized mutations outweigh the known mutations. Thus, there is a greater likelihood of finding patients who have high levels of cAMP produced by the mechanism described in this paper. It is difficult to predict how many patients with increased levels of cAMP will be found in the human population. In any case, the finding that such unique receptor exists in zebrafish suggests that similar receptors may also be present in humans and may lead to novel ways to inactivate these inhibitory receptors to increase cAMP levels. It is also possible that the signalling could contribute to the reduction of phosphodiesterase activity. Future work is needed to identifiy these mechanisms.
Elevated intracellular cAMP in leucocytes in response to microbial invasion has been shown to increase anti-inflammatory cytokines and suppress pro-inflammatory cytokines (Gerlo et al, 2011) . Also, it has been demonstrated that increases in cAMP result in suppression of phagocytosis and microbicidal activity (Serezani et al, 2008) . Thus, the mutant (Schulz & Schoneberg, 2003) . However, humans have only one GPR34 gene, which seems to be closely related to gpr34 type 2. Gpr34l has been classified as an intermediate group consisting of properties of GPR34 and properties of ADP receptors, such as P2Y12. Interestingly, a mutation in the external loop 3 of P2Y12, a related member to Gpr34l has a bleeding phenotype and has been shown to be non-responsive to ADP, but their platelets aggregate in response to epinephrine in contrast to gpr34l mutant which is non-responsive to both ADP and epinephrine (Cattaneo et al, 2003) .
Human GPR34, a closely related member of gpr34 type 2 family, has been shown to be GNAI-linked but it does not respond to lysophosphatidylserine, whereas carp gpr34 type 2 responds to lysophosphatidylserine. However, the introduction of mutations in external loop 2 or in the transmembrane regions corresponding to carp gpr34 type 2 into human GPR34, lead human GPR34 to respond to lysophosphatidylserine (Ritscher et al, 2012) . Further biochemical experiments are needed to determine whether Gpr34l responds to ADP and lysophosphatidylserine. Interestingly, knockout of GPR34 mice showed no obvious phenotypic changes (Liebscher et al, 2011) . We do not know whether the GPR34 knockout mouse has a phenotype similar to zebrafish gpr34l mutant. Nevertheless, Gpr34l seems to have a different mechanism of action and suggests that the mutation we noted is unique.
In summary, we have identified a Gpr34l zebrafish mutant in our mutagenesis screening and have shown that the thrombocytes of these mutants, express constitutive synthesis of cAMP. Our data also show that knockdown of this receptor leads to similarly increased levels of cAMP as that found in mutants. Thus, this finding provides the ground work for searching other such receptors in humans; by modulating such receptors it may be possible to increase cAMP levels to treat not only thrombosis but also disorders where cAMP is required. 
